Scipher Medicine Unveils New Tool to Predict Rheumatoid Arthritis Treatment Success at EULAR 2025
WALTHAM, Mass.--(BUSINESS WIRE)--At the European Congress of Rheumatology (EULAR) 2025, Scipher Medicine, the company behind the groundbreaking PrismRA ® test, unveiled a new, AI-driven approach to help doctors better evaluate if a rheumatoid arthritis (RA) treatment is truly working — a challenge that has long frustrated both patients and physicians.
This new 'RA Response Calculator,' developed using real-world patient data and machine learning, offers a more accurate way to determine whether someone is actually improving on their current therapy — cutting through the noise of subjective measures like patient self-reports and physician assessments.
'Anyone living with RA knows that figuring out whether a medication is working can take months — and even then, it's often unclear,' said Reg Seeto, CEO of Scipher Medicine. 'We created this tool to make that process faster, clearer, and more personalized. It brings science and objectivity to a space that's long relied on educated guesswork.'
The study analyzed data from nearly 1,500 RA patients receiving commonly prescribed treatments — TNF inhibitors, T-cell inhibitors, and IL-6 inhibitors. By applying a machine learning algorithm to joint tenderness, swelling, and inflammation data collected over 24 weeks, Scipher's team identified a combination of two standard clinical measures that best predicts therapy success: Tender Joint Count (TJC) and Swollen Joint Count (SJC).
The result: a simple formula that predicts whether a treatment is helping — or if it's time to try something else.
'Doctors already use TJC and SJC in the clinic. What's new is how we've mathematically combined them using real-world data and AI to create a consistent, data-backed benchmark for treatment response,' said Seeto. 'This is about giving providers and patients a clearer, faster answer — and a better shot at remission.'
The new tool also showed improved accuracy over standard response metrics like CDAI and ACR scores, which are commonly used in trials but often fall short in real-world care.
About Scipher Medicine
Scipher Medicine is transforming how autoimmune diseases like RA are treated by using AI and network biology to match patients with therapies that actually work. Through its SPECTRA Rx and Dx platforms, Scipher combines the largest clinico-genomic dataset in rheumatology with real-world medical records, creating powerful tools to personalize care and improve drug development. Learn more at www.sciphermedicine.com.
PrismRA is a first-of-its-kind blood test that helps doctors identify which RA patients are unlikely to respond to TNF inhibitor therapy — the most commonly prescribed (and most expensive) class of RA drugs. With just a routine blood draw, PrismRA analyzes a patient's molecular signature to guide more effective and personalized treatment plans. Visit PrismRA.com to learn more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Saptalis Pharmaceuticals Launches Fluoxetine Oral Solution, USP 20 mg/5 mL
HAUPPAUGE, N.Y., June 18, 2025--(BUSINESS WIRE)--Saptalis Pharmaceuticals, LLC. is pleased to announce the commercial launch of Fluoxetine Oral Solution, USP 20 mg/5 mL, a prescription-only selective serotonin reuptake inhibitor (SSRI) developed to treat a range of mental health conditions effectively. This oral formulation is designed to support flexible and individualized treatment, particularly for patients who experience difficulty swallowing solid dosage forms. Fluoxetine Oral Solution is indicated for the following conditions: Acute and maintenance treatment of Major Depressive Disorder (MDD) Acute and maintenance treatment of Obsessive-Compulsive Disorder (OCD) Acute and maintenance treatment of Bulimia Nervosa Acute treatment of Panic Disorder, with or without agoraphobia "We are excited to expand our product portfolio with the introduction of Fluoxetine Oral Solution," said Polireddy Dondeti, Ph.D., President and CEO, of Saptalis Pharmaceuticals, LLC. "This launch reflects our ongoing commitment to providing high-quality, accessible medications that meet the evolving needs of both patients and healthcare professionals." Fluoxetine Oral Solution, USP 20 mg/5 mL is available by prescription and should only be used under the guidance of a licensed healthcare provider to ensure safe and effective treatment. For full prescribing information or to learn more, please visit or contact us at info@ About Saptalis Pharmaceuticals, LLC. Saptalis Pharmaceuticals, LLC. is a rapidly growing company focused on the development, manufacturing, and commercialization of specialty pharmaceutical products, including complex and high-quality generics, with particular expertise in liquid and semi-solid dosage forms. Headquartered in Hauppauge, New York, Saptalis operates fully equipped R&D laboratories and a state-of-the-art commercial manufacturing facility compliant with U.S. FDA cGMP standards. The company is dedicated to delivering innovative solutions that enhance patient care and improve treatment outcomes. View source version on Contacts Peruvemba SatishChief Financial Officer & Chief Commercial Officer(631) 231 2751 x211info@ Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Business Wire
25 minutes ago
- Business Wire
Saptalis Pharmaceuticals Launches Fluoxetine Oral Solution, USP 20 mg/5 mL
HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Saptalis Pharmaceuticals, LLC. is pleased to announce the commercial launch of Fluoxetine Oral Solution, USP 20 mg/5 mL, a prescription-only selective serotonin reuptake inhibitor (SSRI) developed to treat a range of mental health conditions effectively. This oral formulation is designed to support flexible and individualized treatment, particularly for patients who experience difficulty swallowing solid dosage forms. This launch reflects our ongoing commitment to providing high-quality, accessible medications that meet the evolving needs of both patients and healthcare professionals. Share Fluoxetine Oral Solution is indicated for the following conditions: Acute and maintenance treatment of Major Depressive Disorder (MDD) Acute and maintenance treatment of Obsessive-Compulsive Disorder (OCD) Acute and maintenance treatment of Bulimia Nervosa Acute treatment of Panic Disorder, with or without agoraphobia 'We are excited to expand our product portfolio with the introduction of Fluoxetine Oral Solution,' said Polireddy Dondeti, Ph.D., President and CEO, of Saptalis Pharmaceuticals, LLC. 'This launch reflects our ongoing commitment to providing high-quality, accessible medications that meet the evolving needs of both patients and healthcare professionals.' Fluoxetine Oral Solution, USP 20 mg/5 mL is available by prescription and should only be used under the guidance of a licensed healthcare provider to ensure safe and effective treatment. For full prescribing information or to learn more, please visit or contact us at info@ About Saptalis Pharmaceuticals, LLC. Saptalis Pharmaceuticals, LLC. is a rapidly growing company focused on the development, manufacturing, and commercialization of specialty pharmaceutical products, including complex and high-quality generics, with particular expertise in liquid and semi-solid dosage forms. Headquartered in Hauppauge, New York, Saptalis operates fully equipped R&D laboratories and a state-of-the-art commercial manufacturing facility compliant with U.S. FDA cGMP standards. The company is dedicated to delivering innovative solutions that enhance patient care and improve treatment outcomes.
Yahoo
an hour ago
- Yahoo
AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)
Clearance Makes Office-Based Procedure Available to a Wider Range of Patients EL SEGUNDO, Calif., June 18, 2025--(BUSINESS WIRE)--KARL STORZ United States is proud to announce that the US Food and Drug Administration (FDA) has cleared an expanded indication for the AventaMed Solo+™ Tympanostomy Tube Device (TTD), allowing its use in pediatric patients aged 6 months and older. This expanded clearance builds on the previous 510(k) clearance, which was indicated for patients 6 to 24 months old. The Solo+ device represents a significant advancement in pediatric ENT care. It is intended to deliver a tympanostomy tube (also known as a ventilation tube) into a patient's tympanic membrane, or eardrum, to treat problems arising from ear infections. Traditionally, this procedure would be performed in an operating room under general anesthesia. The Solo+ device offers a convenient alternative. Using as little as a topical anesthetic, the Solo+ device integrates multiple functions into a single, user-friendly instrument, deploying the tube with the press of a button. As a result, it enables tympanostomies to be performed in an office setting. New clinical findings support the safe and effective use of the Solo+ device, showing that physicians were consistently able to complete the procedure in the office as intended—without needing to move to the operating room. The Solo+ Tympanostomy Tube Device demonstrated consistent, reliable performance across pediatric age groups, with strong follow-up outcomes. These results provide both guardians and physicians with greater confidence in selecting an office-based approach to ear tube placement for a wider range of children. "On behalf of patients and their families, we are excited by this expanded indication," said Chris Smith, VP of Sales & Marketing, Head & Neck Division, at KARL STORZ US. "This makes it possible to offer this effective treatment to a broad population. With clear advantages like avoiding general anesthesia, reducing total procedural costs, and delivering high patient satisfaction, the Solo+ device will benefit doctors and patients alike. It's part of our commitment to provide technology that addresses real-world needs." About Ear Infections Chronic ear infections are a leading reason for doctor visits among young children.1-3 Children are more susceptible to this potentially painful condition, which can adversely affect the ability to hear.1 Treatment often involves procedures known as myringotomy and tympanostomy. Myringotomy involves making an incision in the eardrum to drain excess fluid from the middle ear. It is sometimes performed as a standalone treatment, but is often combined with tympanostomy, in which a tiny tube is inserted in the eardrum to alleviate pressure and allow fluid to drain. The procedure is common: by the age of three, nearly 1 in every 15 children will have had ear tubes.3 About KARL STORZ Since its founding in Germany in 1945, KARL STORZ has grown to become a leading global supplier of endoscopy solutions, including imaging and integration across all sites of care. Now in its third generation, the family-owned company employs 9,400 people in more than 40 countries worldwide. The company acquired the Solo+ technology through the acquisition of AventaMed, which was spun off from Munster Technological University in 2015. For more information, visit 1 Ahmed S et al. Incremental health care utilization and costs for acute otitis media in children. Laryngoscope. 2014;124(1):301-5. doi: 10.1002/lary.24190.2 Bhattacharyya N, Shay SG. Epidemiology of Pediatric Tympanostomy Tube Placement in the United States. Otolaryngol Head Neck Surg. 2020;163(3):600-602. doi: 10.1177/0194599820917397.3 Rosenfeld RM et al. Clinical Practice Guideline: Tympanostomy Tubes in Children. Otolaryngol Head Neck Surg. 2013;149:S1-S35. doi: 10.1177/0194599813487302. View source version on Contacts Susan ManciaMobile: 562-841-1515E-mail:
